Scripps Research, AbbVie Expand Collaboration Beyond Cancer

The collaboration marks an expansion of a partnership launched by AbbVie and Scripps research in 2018 focused on developing T-cell therapies aimed primarily at cancer, including solid tumors, based on an improved CAR-T platform they co-developed.

Scripps Research, AbbVie Expand Collaboration Beyond Cancer

The collaboration marks an expansion of a partnership launched by AbbVie and Scripps research in 2018 focused on developing T-cell therapies aimed primarily at cancer, including solid tumors, based on an improved CAR-T platform they co-developed.
Business people on video conference

Genetic Counseling 2.0

As genetic testing ramps up in the clinic and via consumer-oriented providers, companies leverage technology to scale genetic counseling services.

Blood Test that Measures Expression of 5,000 Proteins Shows Potential as Disease Screening Tool

Researchers scanned 5,000 proteins in single blood plasma samples taken from 16,894 participants to simultaneously capture the individualized imprints of current health status, and incident risk of cardiometabolic diseases such as diabetes, coronary heart disease, stroke,and heart failure.

Introduction to Cell Therapy

Sponsored content brought to you by Cell Therapy Overview CAR-T therapies have quickly shifted the direction of treatments for aggressive diseases, such as blood cancers, where previous treatments were limited. There are currently over 1000 cell and gene therapy trials and two approved cell therapies, axicabtagene ciloleucel and tisagenlecleucel, but...

Small Sequencer Developer GenapSys Completes $90M Series C Financing

GenapSys’ sequencing system is about the size of an iPad, costs under $10,000, and is based on a proprietary direct electronic sequencing chip, which is intended to eliminate the need for cumbersome equipment.
Dendritic cell and T-lymphocytes, illustration

A Power Tool for Immune Profiling

Sponsored content brought to you by How Single-Cell Functional Proteomics Accelerates Immunotherapy Development: Opportunities from Pre-Clinical to Clinical Stages Many companies are racing to develop cancer immunotherapies--a market estimated to be worth $50 billion and expected to grow exponentially over the next several years. Some of the earliest such approved products...
Woman aging

Elysium Health Launches At-Home Test to Measure Rate of Aging, Biological Age

Elysium Heath also announced Morgan Levine, Ph.D., of Yale School of Medicine has joined the company as head of bioinformatics to improve the testing methodology of Index, with the goal of making its application accurate and informative for individuals.

Mayo Clinic Names Head of New Digital Healthcare Platform

John Halamka, M.D., will oversee Mayo Clinic Platform as it carries out initial projects focused on home healthcare scheduling, patient data uploading, and supplying patient-specific treatment information based on Mayo Clinic data.

Promega to Develop MSI Technology as CDx to Merck’s Keytruda

Promega’s MSI testing is designed to functionally measure the genomic accumulation of insertion or deletion (INDEL) errors caused by a deficient mismatch-repair system (dMMR) that occurs in certain types of solid tumors.
Bristol-Myers Squibb (BMS) plans to use Natera's Signatera custom circulating tumor DNA (ctDNA) assay in a Phase II study designed to assess the pharma giant’s cancer immunotherapy Opdivo (nivolumab) as an adjuvant treatment for non-small cell lung cancer (NSCLC). [Source: Eraxion/Getty]

Pre-Surgical Immunotherapy for Lung Cancer Shows Positive Results

Researchers from the Dana-Farber Cancer Institute, Brigham and Women’s Hospital, and nine other centers, presented interim results at the American Society of Clinical Oncology Annual Meeting over the week showing demonstrating that pre-surgical neoadjuvant treatment of lung cancer patients with an immune checkpoint inhibitor was well-tolerated by patients and,...
Illustration of white blood cells attacking a cancer cell

Introduction to Checkpoint Therapy

Sponsored content brought to you by Checkpoint and Combination Therapy Overview Checkpoint immunotherapy development continues to grow at an incredible rate—as of 2018 there were more than 2250 clinical immunotherapy trials incorporating checkpoint therapy, with two of the three largest selling oncology drugs being checkpoint-based immunotherapies. As this field becomes even more...
DNA research concept DNA barcodes for biomedical research  mitochondrial DNA  Prostate cancer DNA test

8 Companion Diagnostic Developers Making a Mark

If companion diagnostics (CDx) were people, they would be old enough to drink. The first CDx won FDA approval in 1998, when Dako Denmark (since acquired by Agilent Technologies) received authorization to market HercepTest. The immunohistochemistry (IHC) assay was designed to detect human epidermal growth factor receptor 2 (HER2)...

LeukoVantage: A Quest/QIAGEN Partnership Providing Clinical Insights Into Myeloid Malignancies

In this webinar, we will describe Quest’s LeukoVantage assay, an NGS test designed specifically for detecting clinically relevant variants in myeloid malignancies, and its partnership with N-of-One, a QIAGEN company, for expert interpretation.

Single-Cell Functional Proteomics Accelerates Immunotherapy Development Opportunities from Pre-Clinical to Clinical Stages

IsoPlexis’ next generation systems provide actionable potency, safety, and patient difference metrics by detecting highly potent single cell functional subsets for the first time.

The Next Era in Pathway Proteomics: Turnkey Targeted Quantitation Workflows

REGISTER NOW Broadcast Date: October 1, 2019 Time: 8:00 am PT, 11:00 am ET, 17:00 CET Accurate monitoring of cell signaling pathway proteins, particularly tyrosine phosphorylation (pTyr)...
Scroll Up